Sustainable innovation in healthcare starts with a deep understanding of the connections between all life forms on Earth 🌍 Human, animal, and plant health are inextricably linked! That's why, as a private equity fund committed to embedding sustainability into every step of our journey, we conducted our first #OneHealth workshop, a collaborative session to explore how these ecosystems are intertwined and how they impact our future. Together, our team tackled some critical questions: 🌿 How does human activity drive biodiversity loss and the emergence of diseases? 🌡️ What role does climate change play in affecting these interdependent health systems? 💡 How we can overcome barriers and leverage opportunities to improve health outcomes for society? This workshop is part of our broader sustainability training program, building on the strong foundations laid by our Climate Fresk initiative. At JEITO, people are at the heart of everything we do. By deepening our understanding of our shared responsibility, we take the first steps toward creating a healthier, more sustainable future for all. 🌱 #sustainibility #ESG #privateequity #innovation #healthcare #environment #biodiversity #finance
JEITO
Directeurs du capital-risque et du capital-investissement
Paris, Île-de-France 6 307 abonnés
Go faster for the Patient, further with the Entrepreneur
À propos
Jeito is a next-generation fund with a patient benefit driven approach, that focuses both on financing ground-breaking medical innovation and promoting positive societal impact. We empower and support entrepreneurs through our expert, integrated, multi-talented team. Jeito Capital is based in Paris with a presence in Europe and the United States. Follow us to get our latest news & job offers.
- Site web
-
http://www.jeito.life
Lien externe pour JEITO
- Secteur
- Directeurs du capital-risque et du capital-investissement
- Taille de l’entreprise
- 11-50 employés
- Siège social
- Paris, Île-de-France
- Type
- Partenariat
- Fondée en
- 2017
- Domaines
- Private equity et Biopharma
Lieux
-
Principal
2, Rue Pillet Will
75009 Paris, Île-de-France, FR
Employés chez JEITO
Nouvelles
-
Congratulations to CDR-Life Inc. teams for the First patient treated with its MAGE-A4-targeting T-cell engager CDR404. 👏 This is a major step achieved in the development of highly tumor-selective immunotherapies for patients suffering from solid tumors, including notably lung, head and neck cancer! The first patient has been dosed as part of a Phase 1 study conducted by our portfolio company, at a time when there is an urgent need for new therapeutic solutions for these patients. The trial, underway in both Europe and the U.S., is evaluating the safety, tolerability and preliminary anti-tumor activity of CDR404 in several common cancers including squamous cell carcinomas. Read more about this new milestone 👉 https://lnkd.in/e2VQrW4X #FasterForThePatient #innovation #immunotherapy #clinicaltrial #biopharma
-
We are very happy to see EyeBio, one of our portfolio companies acquired recently by Merck (MSD) for up to $3 billion, achieving a new major milestone! In collaboration with Merck, the team has now initiated Phase 2b/3b clinical trials for Restoret in Diabetic Macular Edema (DME), right on schedule. This significant progress highlights the strong potential of their pipeline in advancing treatments for back of the eye diseases. Congratulations to all involved in this fantastic step! 👏 #innovation #biopharma #lifescience #ophthalmology https://lnkd.in/e2a5V9Ga
-
The Jeito team is back in action! 💼🚀 We're thrilled to attend IPEM for the 2024 edition, where we look forward to connecting with the key players driving private equity. Visit us at booth h209📍Our team is ready to meet you from September 9th to 11th. Let's discuss the future of innovation in healthcare and biopharma! See you there! #IPEM2024 #privateequity #finance #investment #lifescience #biopharma
-
We are very pleased to share that our portfolio company Noema Pharma announced the completion of enrollment in the GALENE Phase 2B trial evaluating the efficacy of NOE-101 for seizure control in Tuberous Sclerosis Complex (TSC)! 👏 TSC is a debilitating disease characterized by serious, life-threatening seizures with long-term impact on brain development and caused by mutations in the TSC1 and TSC2 genes. Approximately 80,000 people in the US and EU are diagnosed with TSC, and about 60 percent of patients do not respond to current treatment options. Congratulations to the Noema Pharma team for this new achievement! Read more 👉 https://lnkd.in/e-eCrMbm #FasterForThePatient #Innovation #Biopharma #RareDisease #NeuromuscularDisease
Noema Pharma Announces Completion of Enrollment for GALENE Phase 2B Trial Evaluating NOE-101, a First-in-Class mGluR5 NAM, for Seizure Control in Tuberous Sclerosis Complex
https://noemapharma.com
-
🚀 We are very pleased to share that our portfolio company Advesya has received approval from the European Medicines Agency (EMA) to initiate the phase 1/2 trial of its lead asset, CCTx-001, to address the medical needs of patients with acute myeloid leukemia (AML). AML is a cancer of the bone marrow and the blood that progresses rapidly without treatment The #RESOLVE AML 001 study will determine the recommended phase 2 dose of CCTx-001 and will assess safety, tolerability, and clinical activity in patients with relapsed/refractory AML. #biopharma #innovation #hematology #oncology #clinicalstudy
-
We are thrilled to announce JEITO's participation in the $150 million Series D financing of our portfolio company CatalYm GmbH, a clinical-stage biopharma developing novel immunotherapies to fight cancer. Jeito's new investment, alongside international biopharma investors, underscores Catalym’s strong progress and potential to treat patients suffering from the disease. These new funds will support the expansion of the clinical development plan for visugromab, Catalym’s monoclonal antibody designed to neutralize the GDF-15 protein produced by tumors, to confirm this lead asset as a new class of cancer immunotherapy. Remember, the story between CatalYm GmbH and JEITO started in November 2022 after a first investment as co-lead investor of a €50 million Series C financing. This new investment perfectly illustrates Jeito’s refinancing strategy aiming at continuously supporting portfolio companies with both a significant deployment of capital released upon milestones and a wide range of expertise provided by its collective team. Congratulations CatalYm GmbH! 👏 Read more 👉 https://lnkd.in/eRfKBPZi #FasterForThePatient #privateequity #investment #lifesciences #biopharma #immunotherapy #innovation
-
They are the new faces of the NMD Pharma A/S management team ⤵️ Our portfolio company, developing novel and improved treatments for patients living with rare and severe neuromuscular diseases, is bolstering its executive team with three new senior recruits to support NMD Pharma A/S's strong development. ➡ Peter Kasten will join NMD Pharma as VP Finance ➡ Cecilia Sparr Eskilsson as VP Project Management ➡ Maja Nielsen as HR Director of People As NMD Pharma will have launched three Phase 2 trials by the end of the year, their strong experience and talent will play a crucial role in the company's continued success. We wish them a fruitful collaboration! #JeitoPortfolio #leadership #appointment #biopharma #neuromusculardisease https://lnkd.in/gQgrfRiK
NMD Pharma adds new capabilities with several senior recruits to support its growing business and pipeline — NMD Pharma
nmdpharma.com
-
A few weeks after the official signing, Jeito Capital is delighted to share the successful closing of its portfolio company EyeBio by Merck & Co (MSD) for up to $3 billion. This exit comes as the EyeBio team, led by David Guyer, co-founder & CEO, with its co-founder & CSO Tony Adamis, has made tremendous progress over the past two years with Restoret™, EyeBio's promising late-stage candidate for diabetic macular edema. A new hope dawns for patients with sight-threatening eye conditions. Congratulations to all the stakeholders involved in this achievement. 👏 #FasterForThePatient #privateequity #lifesciences #biopharma #ophthalmology
-
For France Biotech's "Investor Views" broadcast, Sabine Dandiguian, Managing Partner, highlighted JEITO's strategy and its fit with the current M&A dynamic as illustrated through Jeito Capital's two recent successful exits. "𝘛𝘰 𝘢𝘯𝘵𝘪𝘤𝘪𝘱𝘢𝘵𝘦 𝘵𝘩𝘦 𝘱𝘢𝘵𝘦𝘯𝘵 𝘤𝘭𝘪𝘧𝘧, 𝘉𝘪𝘨 𝘗𝘩𝘢𝘳𝘮𝘢 𝘤𝘢𝘯 𝘳𝘦𝘭𝘺 𝘰𝘯 𝘵𝘩𝘦𝘪𝘳 𝘪𝘯𝘵𝘦𝘳𝘯𝘢𝘭 𝘳𝘦𝘴𝘦𝘢𝘳𝘤𝘩, 𝘣𝘶𝘵 𝘯𝘰𝘵 𝘦𝘹𝘤𝘭𝘶𝘴𝘪𝘷𝘦𝘭𝘺. 𝘛𝘩𝘦𝘺 𝘢𝘳𝘦 𝘰𝘯 𝘵𝘩𝘦 𝘭𝘰𝘰𝘬𝘰𝘶𝘵 𝘧𝘰𝘳 𝘴𝘵𝘢𝘳𝘵𝘶𝘱 𝘢𝘤𝘲𝘶𝘪𝘴𝘪𝘵𝘪𝘰𝘯𝘴 𝘵𝘰 𝘧𝘪𝘭𝘭 𝘵𝘩𝘪𝘴 𝘦𝘯𝘰𝘳𝘮𝘰𝘶𝘴 𝘷𝘰𝘪𝘥. 𝘑𝘦𝘪𝘵𝘰 𝘪𝘴 𝘱𝘦𝘳𝘧𝘦𝘤𝘵𝘭𝘺 𝘱𝘰𝘴𝘪𝘵𝘪𝘰𝘯𝘦𝘥 𝘵𝘰 𝘴𝘦𝘪𝘻𝘦 𝘵𝘩𝘪𝘴 𝘰𝘱𝘱𝘰𝘳𝘵𝘶𝘯𝘪𝘵𝘺." Watch the full video here 👉 https://lnkd.in/gCCiKxnv #privateequity #finance #innovation #lifescience #pharma #biopharma